This is a repository copy of The RA-MAP Consortium: A working model for academia-industry collaboration.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/126432/

Version: Supplemental Material

Article:

https://doi.org/10.1038/nrrheum.2017.200

© 2017 Macmillan Publishers Limited, part of Springer Nature. This is an author produced version of a paper published in Nature Reviews Rheumatology. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Predictors of Remission
Models of Clinical Remission and Response in RA Patients (3555)

PREVeNTRA
Register of FDRs of RA to evaluate predictors of the development of RA (1846)

Pooled Data from the Control Arm of RCTs

The Immune Toolkit
A standard assay package to measure immune status of patients

Complex Immune Phenotyping

TACERA
Longitudinal observational study of patients with early RA (275)

Vaccine sub study
Immune response in healthy subjects receiving vaccination (49)

Supplementary Figure 1
Early RA patients

Blood & urine taken 3 monthly

**Blood**
- Gene expression (Illumina HT-12)
- Small RNA sequencing (Illumina Hiseq 2500)
- Flow cytometry: (T cells/B cells/NK cells/Treg/Monocyte & DCs Total 127 parameters)
- Proteomics (SOMAscan®)

**Urine**
- Metabolomics (NMR)
- Autoantibody profiling (SeroTag®)
- Genetics (Illumina CoreExome array Illumina iScan)

Whole Blood, PBMC, CD4+cells, CD8+cells, CD14+ cells
Whole Blood
PBMC
Plasma
Plasma
Urine
Serum
Whole Blood

Supplementary Figure 2
MRC Strategy Board

Expert Panel \(\rightarrow\) I&I Steering Group \(\leftarrow\) ABPI

CONSORTIUM MANAGEMENT GROUP

WP Leads, PM, Industry (+ Industry Chair)

PROJECT STEERING COMMITTEE

All partners (+ Academic Chair)

WORKPACKAGE 1

WP Leads + industry partners

Predictors of remission

Early RA LOS

At risk cohort

WORKPACKAGE 2

WP Leads + industry partners

Biomarkers of immune state; Development of toolkit

Phase I

Phase II

Phase III

Validation of toolkit in LOS

Validation in PoC studies; Aligned to Experimental Medicine Studies

Management plan to cover:
- Deliverables
- Milestones + Timelines
- Governance
- Funding for each WP
- WP integration

Core technology/resources:
- Biobanking
- Transcriptomics
- Flow
- Genetics
- Bioinformatics and Statistics

Supplementary Figure 3